Published in Prim Care Companion J Clin Psychiatry on January 01, 2005
Long-acting Injectable Antipsychotics in First-episode Schizophrenia. Clin Psychopharmacol Neurosci (2013) 0.79
Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review. J Gen Intern Med (2016) 0.75
Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care (2004) 9.16
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med (2002) 5.65
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA (2003) 5.19
Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv (2004) 2.94
Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care (2002) 2.68
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry (2003) 2.24
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry (2003) 2.15
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol (2003) 2.06
Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry (2001) 1.91
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry (2003) 1.76
Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry (2001) 1.75
Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry (2002) 1.75
Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull (2004) 1.73
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry (2003) 1.66
Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry (1990) 1.55
Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry (1992) 1.55
Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol (1998) 1.51
The role of cognition in vocational functioning in schizophrenia. Schizophr Res (2000) 1.43
Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res (2003) 1.36
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) (2003) 1.34
Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am (2003) 1.34
Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv (2003) 1.17
Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res (2004) 1.11
Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry (2004) 1.11
Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry (2003) 1.10
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry (2003) 1.10
From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry (1990) 1.08
Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv (2003) 1.07
Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry (2002) 1.04
Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q (1997) 1.04
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry (2002) 1.03
Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther (1994) 1.02
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol (2004) 1.01
The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand (1983) 0.98
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry (2004) 0.96
Outcome measurement in sleep medicine practice and research. Part 1: assessment of symptoms, subjective and objective daytime sleepiness, health-related quality of life and functional status. Sleep Med Rev (2001) 0.95
Focus on protein kinase A and protein kinase C, critical components of signal transduction system, in mood disorders and suicide. Int J Neuropsychopharmacol (2005) 0.92
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res (2002) 0.92
Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm (2002) 0.91
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry (2000) 0.90
Switching antipsychotic therapies. Ann Pharmacother (2000) 0.90
A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol (2000) 0.89
Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder : Symptoms, Quality of Life and Resource Use under Customary Clinical Care. Clin Drug Investig (2004) 0.87
Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatry (2002) 0.87
Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) (2003) 0.87
Dosing and switching strategies for quetiapine fumarate. Clin Ther (2002) 0.87
Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin (2002) 0.86
Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging (2003) 0.86
Clinical guidelines: Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry (2003) 0.85
Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment & Assessment Group. Adv Ther (1999) 0.83
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. Eur Neuropsychopharmacol (2003) 0.83
Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group. Acta Psychiatr Scand (1997) 0.81
[Psychological aspects of depot treatment of schizophrenic syndromes]. Lakartidningen (1980) 0.80
Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr (2004) 0.80
Switching to amisulpride. Curr Med Res Opin (2002) 0.79
Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr Scand Suppl (1994) 0.78
Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res (2004) 0.78
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.78
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. J Clin Psychiatry (2001) 0.78
Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol (2005) 0.78
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. J Clin Psychiatry (2003) 0.77
The influence of risperidone on cognitive functions in schizophrenia. Coll Antropol (2003) 0.77
Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. J Clin Psychopharmacol (2002) 0.77